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Abstract
Hyperactivation of PARP1 is known to be a major cause of necrotic cell death by
depleting NAD+/ATP pools during Ca2+ overload which is associated with many
ischemic diseases. However, little is known about how PARP1 hyperactivity is regulated during calcium overload. In this study we show that ATR kinase, well known
for its role in DNA damage responses, suppresses ionomycin, glutamate, or quinolinic acid-induced necrotic death of cells including SH-SY5Y neuronal cells. We
found that the inhibition of necrosis requires the kinase activity of ATR. Specifically,
ATR binds to and phosphorylates PARP1 at Ser179 after the ionophore treatments.
This site-specific phosphorylation inactivates PARP1, inhibiting ionophore-induced
necrosis. Strikingly, all of this occurs in the absence of detectable DNA damage
and signaling up to 8 hours after ionophore treatment. Furthermore, little AIF was
released from mitochondria/cytoplasm for nuclear import, supporting the necrotic
type of cell death in the early period of the treatments. Our results reveal a novel

Abbreviations: AIF, apoptosis inducing factor; ATM, ataxia telangiectasia mutated; ATP, adenosine triphosphate; ATR, ataxia telangiectasia and Rad3
related; BSA, bovine serum albumin; DAPI, 4′, 6-diamidino-2-phenylindole; DMEM, Dulbecco's modified Eagle's medium; DDR, DNA damage responses;
DMEM, Dulbecco's modified Eagle's medium; ER, endoplasmic reticulum; FBS, fetal bovine serum; Glut, glutamate; HMGB1, high mobility group box 1;
IP, immunoprecipitation; IPed, immunoprecipitated; KD, kinase dead; MNNG, N-methyl-N′-nitro-N-nitrosoguanidine; NAC, N-acetyl-L-cysteine; NAD+,
nicotinamide adenine dinucleotide; PBS, phosphate-buffered saline; PAR, poly (ADP-ribose); PARP1, Poly [ADP-ribose] polymerase 1; PARylation, poly
ADP-ribosylation; PI, propidium iodide; PLA, proximity ligation assay; QA, quinolinic acid; ROS, reactive oxygen species; U2OS, human osteosarcoma
cell line; VE-822, ATR kinase inhibitor; WB, western blot; WT, wild type; Z-VAD-FMK, apoptotic cell death inhibiton.
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ATR-mediated anti-necrotic mechanism in the cellular stress response to calcium
influx without DNA damage signaling.
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IN TRO D U C T ION

An intracellular spike of Ca2+ is cytotoxic and a major cause
of ischemic injuries.1-8 Ca2+ overload plays a critical role in
the pathogenesis of ischemic diseases by inducing cell death
via necrosis, apoptosis, or parthanatos.2,3,9-22 Necrosis is a
major type of ischemic cell death and occurs early after ischemic injuries.2-5,9-17,21-27 Thus, necrosis induced by a calcium
spike contributes to diseases such as heart failure, ischemic
stroke, brain injury, and immune diseases.2,6-8 Despite these,
the molecular mechanisms of Ca2+ overload-induced necrotic
cell death remain elusive.
Necrotic cell death was traditionally thought to be an
uncontrolled process resulting from cellular infection or
physicochemical stress. Necrosis is characterized by cytoplasmic swelling, irreversible and rapid loss of plasma
membrane integrity, and spillage of the intracellular components.28-30 Recently, there has been a growing body of
evidence demonstrating that necrotic cell death also is a
regulated process and plays an important role in maintaining the physiologic health of cell populations.28,31 For
example, necrosis may serve to maintain tissue and organism integrity by initiating inflammatory responses: high
mobility group box 1 (HMGB1) protein, as a nuclear protein that is released from necrotic cells, acts as a signaling molecule to inform neighboring cells that tissue repair
is required.32-35 How necrosis is regulated intracellularly
and how cells respond to the Ca2+ overload stress remains
largely elusive, particularly in terms of the mechanism of
the induced necrosis. Hyper-activation of poly(ADP-ribose) polymerase 1 (PARP1) toward poly-(ADP-ribosyl)
ation (PARylation) has been demonstrated to be a major
cause of necrotic cell death by depleting the NAD+ pool
and, thus, the NAD+ supply for ATP production in mitochondrial, leading to ATP depletion.36-39 Protein
PARylaton is required for many cellular physiological and
pathological processes, including DNA repair and cell
death.40-44 PARP1 is a highly active enzyme and is responsible for producing up to 90% of the poly (ADP-ribose)
(PAR) polymers within cells.45-47 However, hyperactivation of PARP1 leads to excessive consumption of cellular NAD+, which results in blockage of glycolytic activity
followed by a fall in ATP levels and the accumulation of

phosphorylated sugars.48-53 The depletion of the NAD+/
ATP pools leads to necrosis due to metabolic and bioenergetic collapse.54 In addition, upon Ca2+ influx into cells,
mitochondrial activity is decreased, facilitated by further
Ca2+ release from the endoplasmic reticulum (ER), leading to increased levels of reactive oxygen species (ROS)
and reduced levels of ATP, which results in the induction
of necrotic cell death.33,55
Ataxia telangiectasia and Rad3-related (ATR) protein is
a phosphoinositide 3-kinase-related protein kinase and is
well known for its regulatory role in DNA damage responses
(DDR). It is a critical kinase for maintaining genome integrity through its roles in regulating DNA replication and cellular defense responses to DNA damage caused by endogenous
or environmental sources.56-59 In response to DNA damage,
ATR and the related kinase ataxia telangiectasia mutated
(ATM) activate multiple checkpoint-signaling pathways to
arrest the cell cycle, promote DNA repair, and/or apoptosis
to eliminate the damaged cells.60 ATR is activated by DNA
damage-induced replicative stress, while ATM primarily is
activated by DNA double-strand breaks (DSBs).61,62 When
activated, ATR phosphorylates hundreds of downstream protein substrates such as checkpoint kinase 1 (Chk1) and the
tumor suppressor p53,63-65 which are called the mediators or
effectors that carry out specific critical roles in the stress response. ATR phosphorylates substrates at sites with serine
or threonine residues that are followed by a glutamine residue (the SQ/TQ motif).66-68 To our knowledge, there have
been no reported observations that ATR plays a role in programmed necrosis.
This study explores the role of ATR kinase in regulating
Ca2+ overload-induced necrosis in the absence of DNA damage-signaling activation. We demonstrate that the kinase activity of ATR is required to suppress Ca2+overload-induced
necrosis independent of ATR-mediated DNA damage signaling. PARP1-mediated PARylation is the target of ATR's
role in moderating the Ca2+ overload-induced necrosis.
Mechanistically, ATR phosphorylates PARP1 at serine 179,
which suppresses PARylation and, thus, Ca2+ overload-induced necrosis. Our study identifies the ATR protein kinase
as an important new player in regulating necrosis, and our
results highlight a potential application of ATR kinase inhibitors in moderating necrosis-related diseases.

   

LI et al.

2
2.1

|

M ATE R IA L S A N D ME T HODS

|

Cell culture, reagents, and antibodies

Cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% FBS and 1% penicillin/
streptomycin. The ATR inhibitor VE-822 (cat# B1383)
was from ApexBio Technology. Antibodies against phospho-Chk1 (S345; cat# 2348), Chk1 (cat# 2360), actin (Cat#
4970), PARP1 (cat# 9542), cleaved caspases 3 (cat# 9661)
and 7 (cat# 9491), γ-H2AX (A300-081A), ATM (cat#
A300-299A), and GAPDH (cat# 2118) were from Cell
Signaling Technology. The antibody against ATR (cat#
A300-137A) was from Bethyl Laboratories. The phosphoATR antibody (T1989; cat# GTX128145) and HMGB1 antibody (cat# GTX101277) were from GeneTex. Antibody
against poly (ADP-ribose) (PAR) (Cat#4338-MC-50) was
from Trevigin.
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Western blotting

Whole cell lysates were prepared by incubating harvested
cells in lysis buffer [50 mM Tris-HCl pH 8.0, 140 mM
NaCl, 1% Triton X-100, 0.05% SDS, 1 mM EDTA, and
1× protease and phosphatase inhibitors (Roche)] on ice for
10 minutes, and then centrifuged at 20 000 g for 10 minutes at 4°C to clear the lysates. After the addition of an
equal volume of 2 × SDS loading buffer the lysates were
boiled for 10 minutes before separation by SDS-PAGE
for western blot (WB) analysis. After electroblotting onto
PVDF membranes specific proteins were detected using
the antibodies specified above. In most cases, the blots
were probed sequentially with different antibodies without
stripping if the probed proteins have very different molecular weights and migrated as well-separated bands on SDSPAGE. However, there were several cases that the probed
proteins had close migrations on the gels so that blots were
stripped for separate probing.

2.3
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Immunofluorescence microscopy

For immunofluorescence detection of PARP1 protein
and PAR-modified proteins, cells were grown on coverslips before the initiation of experimental treatments.
After treatment, cells were fixed with 4% paraformaldehyde, permeablized with 0.25% Triton X-100 in PBS and
blocked with 5% bovine serum albumin (BSA) for 1 hour
at room temperature. Phosphorylated proteins were detected with the indicated antibodies, and appropriate fluorescence-conjugated secondary antibodies (Thermo Fisher
Scientific). The cells on coverslips were mounted with

|
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ProLong Gold anti-fade reagent containing DAPI (Thermo
Fisher Scientific) before microscopy.
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Duolink proximity ligation assays

For Duolink microscopic detection of protein interactions
cells were grown on coverslips before the initiation of experimental treatments. After ionomycin treatment, cells
were fixed with 4% paraformaldehyde and permeablized
with 0.2% Triton X-100 in PBS and blocked with 3% BSA
in PBS for 1 hour at room temperature. Proteins then were
detected with primary antibodies and the proximity ligation
assay (PLA) assay was carried out according to the company's protocol (Sigma, DUO92101). Images were taken
using the Life Technologies Evos FL Auto microscope or
an Olympus confocal microscope.

2.5
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Subcellular fractionation

Subcellular fractionation was carried out as described previously.69,70 Briefly, cytoplasmic and nuclear extracts were
obtained following the subcellular fractionation protocol of
the ProteoJETTM cytoplasmic and nuclear protein extraction kit (ThermoFisher). Briefly, 10 volumes of cell lysis
buffer (with 1x protease inhibitors) were added to 1 volume of packed cells. After a short vortexing and incubation
on ice for 10 minutes, cytoplasm was separated from nuclei
by centrifugation at 500 g for 7 minutes at 4°C. Isolated
nuclei were washed with 500 uL of the nuclear washing
buffer and collected by centrifugation. The washed nuclei
were lysed in ice-cold buffer (140 mM NaCl, 50mM TrisHCl pH7.8, 10% glycerol, 1% NP-40, and 1 mM EDTA,
with 1X protease and phosphatase inhibitors added freshly
before use) in a 1.5 mL microcentrifuge tube rotated at 4°C
for 15 minutes. Nuclear lysate was the supernatant after
centrifugation at 13 000 rpm for 10 minutes at 4°C. Then
equal volume of 2 × SDS loading buffer was added to each
fraction for western blotting. In all of the fractionation experiments western blotting of either cytoplasmic (β-actin
or GAPDH) and nuclear (PARP) markers were assessed to
check successful fractionation and cytoplasmic and nuclear
protein loading, respectively.

2.6
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Immunoprecipitation

Cytoplasmic and nuclear extracts were collected as described
above.69,70 The extracts were diluted to 1 mL with ice-cold
buffer (50 mM Tris-HCl pH 7.8, 140 mM NaCl, 10% glycerol, 1% NP-40, 1 mM EDTA, plus 1x protease, and phosphatase inhibitor cocktail from Thermo Fisher Scientific).
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For each 1 mg of protein, 1 μL of anti-PARP1 antibody was
added. The mix was incubated overnight at 4°C on a rotator. About 50 μL of Protein G agarose slurry was added to
conjugate the antigen-antibody complex for 4 hours on rotation at 4°C. Bead-bound proteins were collected by centrifugation and washed three times with washing buffer (50 mM
Tris-HCl pH 7.6, 140 mM NaCl, 10% glycerol, 0.2% Tween
20, 1 mM EDTA supplied with proteinase and phosphatase
inhibitors). Proteins on beads were eluted by adding 2 × SDS
loading buffer and boiling for 10 minutes.

2.7
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Exogenous protein expression

For transient transfections, specified cDNA expression plasmids
were diluted into jetPEI DNA transfection reagent; transfection
was done by following the PolyPlus protocol for adherent cells.
Briefly, cells were seeded at 30%-50% confluency 1 day before
transfection which was continued for 48 hours.

2.8 | Isolation of cell clones with stable
protein-expressing constructs
Antibiotic selection was employed 48 hours after transfection
to select cells containing a plasmid construct and to stabilize
the expression of the exogenous protein construct. The antibiotic selection was maintained for 14 days with replacement of
the selective medium every 3 or 4 days. Cells were harvested
and diluted to 1 cell per 0.5 mL culture medium and plated at
0.3 mL per well into 96-well plates. Large and healthy colonies (500-1000 cells) were isolated using sterile 10 μL micropipette tips and expanded in culture medium containing the
appropriate antibiotic. WB analysis was performed to confirm
that cells continue to express the desired protein.

2.9
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Trypan blue exclusion assay

Dead cells with a fractured cell membrane take up the dye
trypan blue. Thus, a trypan blue exclusion assay was employed to determine necrotic cell death. About 0.1 mL of a
0.4% trypan blue stock solution was added to a 1 mL of suspension of cells that were harvested from both attached and
floating cells. The number of blue cells were counted against
total number of cells; the percentage of necrotic cells was
calculated as (# blue cells/# total cells) × 100.

2.10
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Cell titer-blue cell viability assay

The procedure was done by following the protocol of the Cell
Titer-Blue Reagent from Promega. Briefly, cells were seeded

LI et al.

in wells of a 96-well microplate. Cell treatments occurred the
next day, after which Cell Titer-Blue reagent was added at
5 μL per well. The plate was incubated at 37°C for another
2 hours. The fluorescence [560Ex/590Em] was recorded
using a fluorescent microplate reader. This assay is based on
the ability of living cells to convert the cell-permeable redox
dye resazurin to resorufin, which fluoresces at 590 nm. A
decrease in fluorescence intensity reflects a decrease in cell
viability.

2.11
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LDH release assay

The assay measures the lactate dehydrogenase (LDH) released by dying cells into the culture supernatant. The released LDH converts a tetrazolium salt (INT) into a red
formazan product. The amount of color formed is proportional to the number of lysed/dead cells. Briefly, cells were
seeded in wells of a 96-well microplate 1 day ahead of the
cell treatment and assay. The CytoTox 96 Reagent Kit was
employed (Promega cat#G1780). Following experimental
treatment, 50 µL of media from each well are transferred
to another 96-well plate. Several non-treated wells of the
culture plate received a 1:10 dilution of Lysis Solution before the media transfer and incubated for 45 minutes to lyse
all cells as a positive control. For the LDL assay 50 µL of
CytoTox 96 Reagent is added to each well containing 50
µL of transferred media and the assay plate was incubated
for 30 minutes at room temperature, followed by the addition of 50 μL of Stop Solution. The assay plate was incubated for another 15 minutes at room temperature. The
absorbance signal at 490 nM was measured in a microplate
reader.

2.11.1
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Propidium iodide (PI) staining

PI was employed in some experiments to determine the
loss of cell membrane integrity as it enters cells only if
the plasma membrane becomes permeable and stains DNA
and RNA. Hoechst 33343 is a cell membrane-permeable
nuclear counterstain that emits blue fluorescence when
bound to dsDNA. Both dyes were added simultaneously
to determine the ionomycin-induced necrotic cell death.
Briefly, after ionomycin treatment, cells were washed with
37°C-warmed 1 × PBS. PI and Hoechst 33342 were diluted
into 37°C-warmed 1 × PBS at 5 μg/mL and added to the
attached cells and incubated for 10 minutes at 37°C. The
staining mix was then discarded, and cells were washed
with 37°C-warmed 1 × PBS. Images were captured with
an EVOS fluorescent microscope and PI-stained cells were
quantified relative to the total cell number (stained with
Hoechst 33342).
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2.12 | Intracellular calcium concentration
measurement
HCT116 ATR+/+ and ATRflox/− (ATR-proficient and -deficient) cells were grown on glass coverslips and then loaded
with Fura2 for 30 minutes at room temperature. Cells were
washed with PBS to remove excess Fura2 and then transferred to an acrylic chamber on the microscope stage.
Fluorescence measurements were recorded as soon as cells
were placed on the stage (0 min). After 10 minutes the normal media was removed and replaced with media containing
calcium (10 mM) and ionomycin (10 μM) for a 10 minutes
incubation. The media was then removed and replaced with
media lacking calcium. The Fura2 fluorescence was recorded
at 10 seconds intervals with an imaging system composed of
a filter wheel and a Basler A311F VGA camera connected to
an Olympus IX71 inverted microscope. Data collection and
the filter wheel were controlled by Automated In Cyte2 software. Calcium concentration was measured by interpolation
from a standard curve generated by calibration buffer kit #2
(Molecular Probes) and Fura2/K5-salt. Background fluorescence was corrected, and the intensity of the fluorescence
(F340/F380) was monitored in 30-40 cells.

2.13
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Plasmid manipulation

The mammalian expression construct pcDNA3.1-hygroPARP1-Myc-6His was a kind gift from Dr Saraswati
Sukumar (Johns Hopkins University School of Medicine).
Site-directed mutagenesis was done by following the
protocol of the In-Fusion HD Cloning Kit (Clontech
Laboratories). Table 1 lists the primers used in the amplification reactions, for generating potential ATR phosphorylation-deficient mutations of PARP1, for adding a FLAG
tag to the C-terminal of PARP1, and for deleting the extra
codons from the C-terminal of the original construct that
do not belong to PARP cDNA.

2.14

|

FLAG-tagged protein purification

Human HEK293T cells, mammalian expression plasmids
pcDNA3.1-FLAG-ATR and pcDNA3.1-FLAG-PARP1 were
used for recombinant protein purifications. Briefly, HEK293T
cells were seeded overnight ahead of plasmid transfection.
After 48 hours transfection the cells were harvested and lysed
in ice-cold cellular lysis buffer (50 mM HEPES-KOH, pH7.4,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, and 1 × protease and phosphatase inhibitor cocktail) for
20 minutes at 4°C on a rotator. The cell lysate was clarified by
centrifugation at 20 000 g for 10 minutes at 4°C. FLAG M2
magnetic beads were added to each tube of cell lysate, rotated

TABLE 1

|
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Primers that were used for site-directed mutagenesis

PARP1-S179A-F: 5′-GCGGCTCAGCTCAAGGGCTTCAGCCT
CCTTGCTAC-3′
PARP1-S179A-R: 5′-CTTGAGCTGAGCCGCACTGTACTCGG
GCCGGAAAC-3′
PARP1-T325A-F: 5′-GTCAAGGCACAGACACCCAAC-3′
PARP1-T325A-R: 5′-TGTCTGTGCCTTGACCATACACTTG-3′
PARP1-T368A-F: 5′-GCCGCGCCTCCGCCCTCCACAGCCTC
GGCTCCTGCT-3′
PARP1-T368A-R: 5′-GGGCGGAGGCGCGGCCGCCACGGAG
GCGCTGGTT-3′
PARP1-S721A-F: 5′-GCGGTGGCTCAGGGCAGCAGCGACTC
TCAGATCCTGGAT-3′
PARP1-S721A-R: 5′-GCCCTGAGCCACCGCCTGCTGGACCTC
ACTGAGGATGGA-3′
PARP-1-S727A-F: 5′-CGACGCTCAGATCCTGGATCT-3′
PARP-1-S727A-R: 5′-AGGATCTGAGCGTCGCTGCT-3′
PARP1-S874A-F: 5′-GGATCCTGGCTCAGGGTCTT-3′
PARP1-S874A-R: 5′-CCTGAGCCAGGATCCCAGCAAA-3′
PARP1-S911A-F: 5′-ACTGCCATACGGCTCAGGGAGA-3′
PARP1-S911A-R: 5′-GAGCCGTATGGCAGTAGTTGGC-3′
PARP1-FLAG-F: 5′-GACTACAAAGACGATGACGACAAGTA
ACTCGAGTCTAGAGGGCCCGTT-3′
PARP1-FLAG-R: 5′-GACTACAAAGACGATGACGACAAGTA
ACTCGAGTCTAGAGGGCCCGTT-3′
PARP1-DelC-F: 5′-CTGTGGTAACTCGAGTCTAGAGGGCC
CGTT-3′
PARP1-DelC-R: 5′-CTCGAGTTACCACAGGGAGGTCTTAA
AATTGAATTTCAG-3′

for 4 hours at 4°C, and then collected with a magnetic rack.
The collected beads were washed twice with buffer A (50 mM
HEPES-KOH, pH7.4, 150 mM NaCl, 10% glycerol, 1 mM
EDTA, and 0.05% NP-40), a high salt wash (50 mM HEPESKOH, pH7.4, 1 M NaCl, 1 mM EDTA, and 0.05% NP-40) for
2 minutes on a rotator, and a final two washes with buffer A.
Recombinant protein was eluted from the beads with 0.1 mL
of elution buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
10% glycerol, 100 μg/mL FLAG peptide, and 1 mM DTT)
for 4 hours at 4°C on a rotator. The purity of the isolated proteins was determined by SDS-PAGE followed by Coomassie
blue gel staining; their concentrations were determined by
Coomassie blue binding using standard curves of serial dilutions of BSA. The eluted proteins were saved as aliquots that
were snap frozen in liquid nitrogen and stored at −80°C.

2.15
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In vitro PARylation

The in vitro PARylation assay was done similarly as described by others.71,72 Briefly, PARP1 (20 nM) (Thermo
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2.16

Fisher Scientific or Flag-tag purified) and/or ATR (40 nM)
(from our FLAG-tagged protein purification) were incubated
at 4°C in a PARylation reaction buffer (100 mM Tris-HCl
pH7.8, 10 mM MgCl2, 1 mM DTT, 25 μg/mL activated DNA
oligo, and 200 μM NAD+) in a total volume of 40 μL in
1.5 mL micro-centrifuge tubes. The reaction was started by
adding 200 μM 32P-NAD+ and increasing the temperature to
30°C for a 30 minutes incubation, then stopped by adding 2X
SDS loading buffer with heating at 60°C for 5 minutes.

|

In vitro phosphorylation

Cell extracts were prepared from HEK293T cells that were
treated with 10 μM ionomycin for 2 hours followed by cell
lysis for 10 minutes on ice in IP buffer (50 mM Tris-HCl, pH
7.8, 150 mm NaCl, 0.5% Nonidet P-40, 1 mM sodium fluoride, 10% glycerol, and 1 × protease and phosphatase inhibitor
cocktail). Clarified supernatants were subjected to immunoprecipitation with anti-ATR antibody (Bethyl A300-137A)
(B)

(A)

(C)

(D)

(G)

(I)

(E)

(F)

(H)
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F I G U R E 1 ATR inhibits intracellular Ca2+-induced necrosis. A, HCT-116 ATR+/+ and ATRflox/− cells were treated with either ionomycin
(10 μM, 4 h) or the apoptosis inducer camptothecin (CPT) (10 μM, 24 h) followed by phase-contrast imaging (20X). Necrosis, characterized by
cellular swelling and nuclear shrinkage (yellow arrows), was exclusively induced by ionomycin treatment. B, Quantitation of the morphologic
analysis of the three experiments as shown in (A). C, WB analysis of ATR levels in ATR+/+ and ATRflox/− cells. D, Human A549 cells were
transfected with siRNA specific for ATR followed by ionomycin treatment as indicated, then the percentage of cell death was measured via the
trypan blue exclusion assay. E, Human SH-SY5Y neuronal cells were pre-treated with vehicle control or 80 nM of ATR inhibitor VE-822 (ATRi)
for 30 min, then treated with glutamate (Glu, 100 µM), quinolinic acid (QA, 1 mM), or ionomycin (Iono, 5 μM) for 4 h. Cells were harvested and
stained with trypan blue for necrotic cell counting. F, HCT-116 ATR+/+ and ATRflox/− cells were treated with ionomycin for 4 h. HMGB1 released
into the media was assessed by WB using the amount of GAPDH in the whole cell extract as loading control. G, WB analysis of the cleavage
of caspase-3 and caspase-7 in ATR+/+ and ATRflox/− HCT-116 cells treated with either ionomycin or CPT as in (B). H, HCT-116 ATR+/+ cells
were pre-incubated with apoptosis inhibitor Z-VAD-FMK (10 μM, 1 h) and/or ATR kinase inhibitor VE-822 (10 μM, 1 h) followed by mock or
ionomycin treatment (10 μM, 4 h). The percentage of necrotic cell death was measured using the trypan blue exclusion assay. I, Cells were treated
with ionomycin (10 µM, 4 h) or MNNG (250 µM, x h; positive control), followed by fractionation and WB analysis. Quantitative data are shown is
in Mean ± SD of triplicated experiments

and protein A/G-agarose. The beads were washed three times
with cell lysis buffer followed by two washes with kinase
buffer (20 mm HEPES-KOH, pH 7.5, 50 mM NaCl, 10 mM
MgCl2, 1 mM dithiothreitol, and 10 mm MnCl2). Finally,
the immunoprecipitant was resuspended in 25 μl of kinase
buffer containing 10 μCi of [γ-32P]ATP, 100 μM cold ATP,
and 1 μg recombinant PARP1 protein substrate. The kinase
reaction was conducted at 30°C for 20 minutes and stopped
by the addition of 2X SDS-gel loading buffer. Proteins were
separated by SDS-polyacrylamide gel electrophoresis and
transferred to PVDF membrane. Immunoprecipitated ATR
and recombinant PARP1 were confirmed by western blotting. Radiolabeled proteins were visualized and quantitated
on a PhosphorImager (FUJI).

2.17
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Statistics and reproducibility

All data used for statistical analysis were from at least three
repeats. Unpaired two-tailed t tests were performed to compare differences between two groups. One-way ANOVA was
used to determine differences among the means of three or
more groups. An unpaired two-tailed t test was performed
to confirm where significant differences occurred within
groups. A P-value <.05 was considered significant and is indicated by “*” in the figures.
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R E S U LTS

3.1 | ATR suppresses Ca2+ overloadinduced necrosis following calcium ionophore
treatment
Under physiological conditions, cells maintain a low cytosolic free-Ca2+ concentration of ~100 nM relative to the
~1.2 mM extracellular concentration. An increase of cytosolic Ca2+ to 200-400 nM may induce apoptosis.73 In contrast, a spike to a higher concentration of cytosolic Ca2+

due to uncontrolled influx across the plasma membrane
may trigger necrosis.33,74 We initially explored ATR's role
in Ca2+ overload-induced necrosis after treating ATRdeficient cells (ATRflox/−) and the parental wild-type HCT116 cells (ATR+/+) with ionomycin (Figure 1A-C). This
Ca2+ ionophore dramatically raises intracellular levels of
Ca2+ (Figure S1A).74 Morphological analysis of the cells indicated that ~30% of the ATRflox/− cells underwent necrosis,
characterized by cell swelling and plasma membrane rupture
(Figure 1A,B), which was over two-fold higher than ionomycin-treated ATR+/+ cells which displayed ~13% necrotic
death; untreated ATR+/+ cells exhibited little or no necrosis.
Treatment of the cells with camptothecin, a topoisomerase
I inhibitor, was employed as a control showing significant
induction of typical apoptotic cells characterized by cell
shrinkage and formation of apoptotic bodies (Figure 1A). A
similar higher level of necrotic cell death was observed using
the standard trypan blue exclusion assay in cells with siRNA
knockdown of ATR (Figure 1D), and in multiple cell lines
including primary human fibroblasts (Figure S1B,C).
We then assessed the effects of ATR kinase inhibition on
necrosis with a mimicking cell system more relevant to brain
ischemia. In this case, SH-SY5Y neuronal cells were treated
with glutamate (Glut), quinolinic acid (QA), or ionomycin to
induce an intracellular Ca2+ spike in the cells with or without ATR kinase inhibition. Glutamate and quinolinic acid are
two known physiological and pathological stimuli that bind
to glutamate receptors such as the NMDA receptor of neural
cells to trigger an influx of extracellular calcium into these
cells. As shown in Figure 1E, the remarkable similarity and
consistency of the effect of ATR's inhibition on necrotic cell
death were observed in SH-SY5Y cells among these stimuli.
The inhibition of ATR kinase significantly increased necrotic
cell death in each of these conditions, suggesting the relevance of the effects to ischemic conditions. This implies that
ATR may play a general role in suppressing calcium overload-induced necrosis.
Under our experimental condition, calcium influx into
cells induced only necrotic cell death, as demonstrated by
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(A)

(B)

(C)
(D)

(E)

F I G U R E 2 ATR kinase is not activated toward Chk1 phosphorylation during Ca2+ overload-induced necrosis. A, A549 cells were treated
with 20 J/m2 UV-C and allowed to recover or with 10 μM ionomycin for indicated times. WB assessed the kinase activity of ATR toward its DDR
substrates Chk1 and H2aX. B, Chk1 was silenced by siRNA knockdown. At 48 h post-transfection, cells were treated with 10 μM ionomycin for
4 h, and the percent necrotic cells determined by the trypan blue exclusion method (mean ± SD of triplicated experiments). C, WB analysis of
Chk1 knockdown efficiency. D, A549 cells were pre-incubated with mock or 1 mM N-acetyl-L-cysteine (NAC) for 1 h, then 10 μM ionomycin was
added and incubation continued for another 4 h. Mean ± SD of three replicates on the percentage of necrotic cells is shown. E, Cells were treated
with ionomycin (20 µM), CPT (20 µM) or mock-treated and then subjected to an alkaline comet assay analysis. Quantitation was performed based
on over 100 cells each sample

morphological analysis (Figure 1A,B) and the membrane
breakage-associated release of HMGB1 (Figure 1F). No
traceable amount of apoptotic cell death was be detected
by morphological analysis (Figure 1A,B) or the cleavage of
caspases 3 or 7 (Figure 1G) or PARP1 (Figure S1D). The
involvement of ATR in the induced necrosis was validated
further using the inhibitor VE-822 which demonstrated
that inhibition of ATR elevated the necrosis by ~2 fold

(Figure 1H). VE-822 is a potent ATR kinase-specific inhibitor that is currently in phase II clinical trials for cancer treatment and has been widely used in ATR studies. No changes
in the level of necrosis were observed by treatment with the
apoptotic cell death inhibitor Z-VAD-FMK (Figure 1H),
further indicating that necrosis is the dominant form of
cell death under our ionomycin treatment. Upon DNA
damage AIF (Apoptosis-Inducing Factor) is released from
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mitochondria and migrates to the nucleus to induce apoptosis. Thus, we also examined the possible involvement of AIF
in ionomycin-induced cell death. As shown in Figure 1I, little AIF was accumulated in nuclei after ionomycin treatment
of cells relative to the nuclear accumulation of AIF after
treatment with the DNA damaging agent N-methyl-N′-nitroN-nitrosoguanidine (MNNG). These data indicate little or
no activation of AIF by ionomycin treatment.
Interestingly, the canonical ATR DNA damage signaling
cascade through Chk1 and H2AX was not observed in cells
treated with ionomycin (Figure 2A,B), even with a prolonged
24 hours treatment. These results suggest that the activity of
ATR under Ca2+ overload was not related to a DNA damage response, at least not for the first 24-hour period. This
contrasts with the traditional view that ATR functions only
as a guardian of the genome. In addition, efficient knockdown of Chk1, the major mediator of ATR-anchored DNA
damage signaling, did not affect Ca2+ overload-induced cell
death (Figure 2B,C). Preincubation of cells with the antioxidant N-acetyl-L-cysteine (NAC) had little or no effect on
necrotic cell death (Figure 2D), suggesting that an increase
in reactive oxygen species (ROS) is not critical for the Ca2+
overload-induced necrotic cell death during the early hours
of treatment. Furthermore, the ionomycin-treated cells also
were assessed by the comet assay, showing little or no DNA

(A)
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breaks produced in cells (Figure 2E). In contrast, CPT treatment, as a positive control, generated a large amount of DNA
damage. Together, all these results support a role of ATR in a
novel non-DNA damage response to Ca2+ overload.

3.2 | Kinase activity of ATR is involved
in the inhibition of necrotic cell death
Our data in Figure 1H implies a role of ATR kinase activity in suppressing Ca2+ overload-induced necrosis.
Autophosphorylation of ATR on threonine 198975,76 is
a marker for and a switch of ATR to kinase-active status.
To assess if ATR kinase is active after the treatment we examined the level of ATR phosphorylated on T1989 [pATR
(T1989)] as an indicator of kinase activity and observed a significant upregulation after ionomycin treatment (Figure 3A).
We then transfected ATRflox/− cells with wild-type (WT) or
kinase dead (KD) ATR expression constructs and assessed
the level of necrotic cell death by propidium iodine staining (Figure 3B-D). A ~2-fold increase in necrotic cell death
was observed (Figure 3B,C) in cells expressing ATR-KD,
which is similar to the degree of necrotic death with ATR
kinase inhibition (Figure 1H), ATR deficiency (ATRflox/−,
Figure 1B,C), and ATR knockdown (Figure 1D).

(B)

(C)

(D)

F I G U R E 3 The anti-necrotic function of ATR is dependent on its kinase activity. A, WB analysis of ATR phosphorylation on T1989 in A549
cells after UV-C irradiation (40 J/m2, 2 h recovery) or 10 µM ionomycin for the times indicated. B and C, ATR-WT and ATR-KD plasmids were
transfected into ATRflox/− cells and, at 48 h post transfection (~70% efficiency), treated with ionomycin (10 μM, 4 h). The percentage of necrotic
cell death was assessed using the PI and Hoechst staining assay followed by fluorescent microscopy (B) and quantified as the mean ± SD of three
independent experiments (C). D, WB analysis of ATR-WT and ATR-KD protein expression by constructs in ATR-deficient cells (Flox/-) using
anti-ATR antibody
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(B)

(A)

(C)

(D)

(E)

(F)

(G)

F I G U R E 4 PARP1 is the mediator of the anti-necrotic role of ATR kinase. A, Stable A549 shCtrl and shPARP1 cells were mock or
ionomycin treated for 2 h, followed by PI and Hoechst staining. B, Quantitation of the mean ± SD of three independent experiments as shown in
(A). C, WB analysis of PARP1 expression in A549 shCtrl and shPARP1 cells. D and E, U2OS-WT, U2OS PARP1 knockout (PARP−/−), and the
PARP1 knockout cells stably transfected with empty vector (Vector) or wild-type PARP1 (WT) were treated with 10 μM ionomycin or vehicle
control (Mock), followed by trypan blue staining. The mean ± SD data on necrotic cells from three biological repeats and the level of PARP1
expression are shown in (D) and (E), respectively. F, U2OS (PARP+/+) and U2OS PARP1 knockout (PARP1−/−) cells were preincubated with ATR
inhibitor VE-822 (80 nM, 30 min), followed by 10 μM ionomycin for 2 h followed by trypan blue staining. G, A549 cells were supplemented with
or without β-NAD+ (10 mM) for 1 h, followed by treatment with ionomycin (10 μM, 2 h), and the mean ± SD from three independent experiments
on cell viability via the LDH assay are shown

3.3 | PARP1 is a causative factor of the Ca2+
overload-induced necrosis and is inhibited by
ATR kinase
Ca2+ overload leads to hyper-activation of PARP1 and excessive consumption of NAD+ in cells, which is a well-known
cause of necrotic cell death by causing ATP depletion.36,46,49,51
We hypothesized that PARP1 is a mediator of ATR's role in
moderating Ca2+ overload-induced necrosis. shRNA knockdown (Figure 4A-C and Figure S2), knockout (Figure 4D,E),
or inhibition (Figure S2) of PARP1 in cells reduced Ca2+

overload-induced necrosis following ionomycin treatment.
Importantly, the reduced necrotic cell death in PARP1-null
cells (PARP1−/−) was restored by expressing exogenous
PARP1 (Figure 4D,E and Figure S2C), consolidating that the
Ca2+ overload-induced necrosis is dependent on PARP1 and
PARylation. Inhibition of ATR kinase elevated the level of
necrotic cell death in PARP1+/+ cells but has no such effect
in the PARP1−/− cells (Figure 4F), suggesting that PARP1 is,
indeed, the major mediator of ATR's anti-necrotic role in the
Ca2+ overload-induced necrotic responses. In addition, supplementing cells with β-NAD+ reduced necrosis (Figure 4G),
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(D)

(F)

(G)

F I G U R E 5 ATR kinase inhibits intracellular Ca2+-induced PARylation by PARP1. A, A549 cells were treated with ionomycin (10 μM, 4 h)
with or without PARP1 inhibitor 3-ABA at the indicated concentrations. The level of PAR polymers in the cells are detected by WB analysis using
anti-PAR antibody. B, A549 cells were transfected with siRNA specific for PARP1 (siPARP1) or a scrambled siRNA (siCTRL) for 48 h, followed
by ionomycin (10 μM) or mock treatment for the indicated times. Cell lysates were analyzed by WB for PARylation using anti-PAR antibody. C,
WB analysis of PAR polymers in HCT116 ATR+/+ and ATRflox/− cells that were treated with ionomycin (10 μM) for the times indicated. D, WB
analysis of PAR polymers in A549 cells treated with ionomycin (10 μM, 4 h) in the presence or absence of ATR kinase inhibitor VE-822 (10 μM,
1 h pre-incubation). E and F, A549 cells were transfected with siRNAs targeting ATR, ATM or a scrambled siRNA (siCtrl), and the efficiency of
knockdown were confirmed with WB (E). Cells then were treated with 10 μM ionomycin for 4 h and the percentage of dead cells (left panel) and
live cells (right panel) were assessed using the trypan blue exclusion and Cell Titer-Blue assays, respectively. The data are shown as mean ± SD
of three repeats (F). G, The in vitro PARylation activity of PARP1, as affected by recombinant ATR protein or chemicals, was assessed using a
PARylation assay in presence of 32P-NAD+. PARP1, which had incorporated 32P-NAD+, was separated on an 8% SDS-PAGE gel, transferred to
PVDF membrane and the PARylated PARP1 was displayed by autoradiographic imaging
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further supporting the role of PARP1 as the causative factor
of Ca2+ overload-induced necrosis. These findings also suggest an underlying mechanism requiring PARP1-mediated
PARylation in this necrotic cell death.

3.4 | Ca2+ overload induces PARP1mediated hyperPARylation which is inhibited
by ATR kinase
The above data identified an anti-necrotic role of ATR in Ca2+
overload-induced necrosis, which is through PARP1 depletion of NAD+. We further explored the mechanisms through
which ATR may inhibit the PARP1-mediated necrotic activity in response to Ca2+ overload. We first determined the
level of PARylation after Ca2+ overload. Ionomycin-induced
Ca2+ overload robustly increased the level of PARylation
(Figure 5A,B). Over 80% of the elevated PARylation was
inhibited by PARP1 inhibitor 3-ABA or PARP1 knockdown (Figure 5A,B), suggesting that PARP1 is the enzyme
responsible for most of the PARylation in response to Ca2+
overload. ATR deficiency further increased the Ca2+ overload-induced PARylation, particularly at the later time points

LI et al.

F I G U R E 6 Ca2+ overload induces
ATR-PARP1 complex formation. A, A549
cells were treated with ionomycin (10 μM)
for 4 h before subcellular fractionation.
ATR was immunoprecipitated (IPed) from
both cytoplasmic and nuclear fractions (CyF
and NuF, respectively), using anti-ATR
antibody. The coimmunoprecipitation of
PARP1 with ATR was analyzed by WB
(left panel). IPed ATR was also subjected
to a high salt wash to remove endogenous
PARP1 and then was incubated with
purified recombinant PARP1 in a binding
buffer. After incubation the ATR was IPed
again and the amount of bound PARP1
measured by western blot analysis (right
panel). B and C, A549 cells were treated
with ionomycin (10 μM, 2 h) followed by
the proximity ligation assay (PLA) to detect
ionomycin-induced ATR-PARP1 binding.
Red dots indicate ATR-PARP1 complex
formation under fluorescent microscopy (B).
The quantitation of the mean ± SD of the
foci in the PLA assay of 100 cells is shown
in (C)

(between 2 and 4 h) of ionomycin treatment (Figure 5C)
when cells started to die (Figure S1B,C). In addition, in a
dose-dependent manner, inhibition of ATR kinase increased
Ca2+ overload-induced PARylation (Figure 5D).
Interestingly, siRNA knockdown of ATM, a similar
DNA damage checkpoint kinase, did not elevate the level of
PARylation as did the knockdown of ATR kinase (Figure 5E,F),
suggesting that ATR's responses to cellular Ca2+ overload
is unique. Further studies demonstrate that Ca2+ stimulates
PARP1-mediated in vitro PARylation activity (Figure 5G left)
and that addition of purified ATR protein inhibited the extension of PARylation and PARs remain short. Interestingly, when
short double-stranded oligonucleotides, which represent DNA
double-strand breaks, were added to stimulate basal PARP1 activity as a positive control, the inhibitory effect of ATR on extension of PAR polymers, though still obvious, was over-shadowed
by strand break-induced additional PARylation and extension
(Figure 5G right). This suggests that PARP1 may be activated
by Ca2+ overload and DNA damage in different ways, which
is consistent with our observation that Ca2+ overload produced
little DNA damage signaling during necrosis of cells. As such,
our results indicate that ATR inhibits intracellular Ca2+ overload-induced PARylation.
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3.5 | Ca2+ overload induces ATR-PARP1
binding, and subsequent phosphorylation of
PARP1 by ATR to suppress PARylation and
necrotic cell death
Having determined that ATR kinase inhibits PARP1mediated PARylation to suppress Ca2+ overload-induced necrosis, we investigated the mechanisms by which ATR works

(B)

(C)

(E)

(F)
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through PARP1, possibly by phosphorylation of PARP1. We
first examined possible ATR-PARP1 binding in different
cell lines treated with ionomycin to induce necrosis. After
mock or ionomycin treatment ATR was immunoprecipitated from nuclear lysates of A549 cells (Figure 6) or from
whole cell lysates of HCT-116 cells (Figure S3). As shown in
Figure 6A, the immunoprecipitated ATR pulled down significantly more nuclear PARP1 with than without Ca2+ overload

(A)

(D)
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F I G U R E 7 ATR phosphorylation of PARP1 at Ser179 inhibits PARylation and decreases Ca2+ overload-induced necrosis. A, A549 cells were
treated with ionomycin (10 μM, 2 h) in the presence or absence of ATR kinase inhibitor VE822, followed by PLA to detect ionomycin-induced
ATR-PARP1 interaction. Fluorescent foci (ATR-PARP1 interaction) per cell were quantified from three independent measurements. B, Mapping
of the ATR phosphorylation site in PARP1 that is required for inhibition of Ca2+ overload-induced necrosis. The serines in all SQ/TQ sites in
PARP1 predicted as phosphorylation candidates for ATR kinase were mutated to Ala. These mutants and the WT constructs were transfected into
U2OS PARP1 knockout cells. Stable clones expressing these constructs were treated with ionomycin (10 µM, 2 h) and necrotic cell death assessed
by trypan blue staining from three repeats. The first two lanes are the U2OS PARP1 knockout cells with PcDNA3.1 empty vector transfection
(Vec). C, WB analysis determined that similar levels of PARP1 were expressed in each PARP1-containing cell line. D, In vitro phosphorylation
of PARP1-WT and PARP1-S179A by immunoprecipitated ATR from ionomycin-treated (10 μM, 2 h) HEK293T cells. WB analysis demonstrated
that equivalent levels of ATR and PARP1 were employed. The phosphorylation status of PARP1 was monitored by detecting the amount of 32P
incorporated into the recombinant PARP1 proteins (bottom panel). E, Coomassie-stained SDS-PAGE gel showing a major single band both in
purified PARP1-WT and PARP1-S179A lanes. F, The level of PARylation was assessed in the parental U2OS wild type (PARP1+/+) cells, and
U2OS PARP1 knockout cells (PARP1−/−), cells with empty vector (Vec) or stably expressed PARP1+/+ (WT) or PARP1-S179A (S179A) proteins

(left) and this was confirmed by an in vitro binding assay
showing ATR interaction with purified recombinant PARP1
(right). This complex formation was further confirmed by
the Duolink proximity ligation assay (PLA) (Figure 6B,C);
this is an effective complement to the immunoprecipitation
assay because it assesses protein complex formation in cells
after fixation. Given the fact that ATR prevented extension of
PAR formation during PARylation (Figure 5), these results
suggest that ATR may recognize and bind to PARP1 monoPAR or a short polymer of PAR after Ca2+ overload.
We, therefore, hypothesized that this ATR-PARP1 complex formation may reflect ATR interacting with and then
phosphorylating PARP1. Indeed, inhibition of ATR kinase
activity by the specific inhibitor VE822 dramatically reduced ATR-PARP1 association as demonstrated by PLA
assay (Figure 7A). We analyzed the PARP1 protein sequence (NCBI Ref Seq: NP_001609.2) and identified six
potential SQ/TQ motifs as candidates for ATR phosphorylation66,67,77: serine 179, threonine 325, serine 721, serine
727, serine 874, and serine 911 of PARP1. We examined
the effects of the potential phosphorylation on necrotic cell
death by individually mutating each of these six amino acids
to alanine (Figure 7B,C). Among the U2OS PARP1 knockout cells that stably express similar levels of WT or different PARP1 mutants (Figure 7C), PARP1-S179A is the only
mutation that elevated necrotic cell death (Figure 7B). We
then assessed the capability of immunoprecipitated ATR to
phosphorylate PARP1 in an in vitro kinase assay, supplying
purified PARP1-WT and PARP-S179A proteins from ionomycin-treated cells as substrates. ATR was able to add 32P to
purified PARP-WT but much less 32P was added to PARPS179A (Figure 7D), suggesting that S179 of PARP1 is indeed
a site that is directly phosphorylated by ATR. It should be
noted that the minimal amount of phosphorylation on PARPS179A mutant may suggest the possibility that ATR also
could phosphorylate other SQ/TQ sites of PARP1 though it
is minor and might not be involved in necrosis regulation.
The specificity of the phosphorylation of PARP1 by ATR
was verified by pretreatment of immunoprecipitated ATR
with ATR inhibitor (80 nM), which significantly reduced the

in vitro PARP1 phosphorylation (Figure S4) (the remaining
phosphorylation of PARP1 in the presence of ATRi is likely
due to the incomplete inhibition by the inhibitor or the necrosis-independent phosphorylation or both). In addition,
functionally, cellular PARP1-S179A showed a higher basal
activity and Ca+2-induced hyperactivity of PARylation, particularly after the cells were treated with ionomycin to induce
necrosis (Figure 7F). Interestingly, the background PAR level
in the PARP1-S179A mutant cells (no ionomycin treatment)
is significantly higher than in the WT cells. This is consistent
with the result in Figure 5C where ATR deficient cells had a
much higher background PAR level than WT cells (0 h ionomycin treatment), further supporting PARP1-S179's essential
role in PARP1 activity. These data suggest that the phosphorylation of S179 is necessary and sufficient for ATR inhibition
of PARP1 PARylation activity.
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DISCUSSION

We report here that ATR suppresses Ca2+ overload-induced
necrotic cell death, independent of DNA damage and AIF
activity. The activation of ATR kinase activity is not related
to DNA damage signaling, the well-accepted role of ATR.
Rather, ATR kinase is activated in response to Ca2+ overload
and phosphorylates PARP1 on serine 179 in the absence of
detectable DNA damage signaling. The phosphorylation of
PARP1 suppresses PARP1-mediated PARylation and the necrotic cell death induced by Ca2+ overload.
It is well known that Ca2+ overload-induced necrosis contributes to diseases such as heart failure, ischemic
stroke, brain injury, and immune diseases, typically involving early necrosis and delayed apoptosis.2-13,15,17,78,79
Necrosis is responsible for the initial or early cell death
during ischemia.2,11,17 The extent and degree of PARP1
hyperactivation has been demonstrated to be a cause of
necrotic cell death by consuming NAD+ leading to ATP
depletion.36-39 It is worth mentioning that necrosis as described here and parthanatos are both driven by hyper-activation of PARP, but occur via two different mechanisms18:
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Necrosis is characterized by NAD+/ATP depletion,9,17-19
while parthanatos involves DNA damage, AIF activation and inhibition of glycolysis rather than NAD+/ATP
depletion.19,80-82 Our results successfully recaptured the
fundamental mechanisms that cells use to initiate necrosis during Ca2+-overload (Figures 4 and 5). However, little is known about how PARP1 activity is regulated. In
the current study, our results show that, in contrast to the
phosphorylation by Chk2 to activate PARP1 in the DDR,83
ATR phosphorylation of PARP1 in response to Ca2+ overload inhibits its PARylation activity. Consistently, PARP1
appeared to be activated differently by DNA damage and
Ca2+ overload (Figure 5G); in the former case, PARP1 is
activated (but not hyper-activated) to promote the DDR,
while in the latter PARP1 is hyper-activated to induce necrosis which is inhibited by ATR. Specifically, the current
study showed that phosphorylation of PARP1 at serine
179 by ATR is necessary for ATR suppression of Ca2+overload-induced necrosis (Figure 7D). Our finding that
PARP1 with a point mutation at this phosphorylation site
(Ser179Ala) showed elevated PARylation activity, with
and without Ca2+-overload (Figure 7F), strongly supports
this proposed mechanism. It is possible that the phosphorylation of PARP1 may have similar roles in other stress
responses, since phosphorylation of this same site has been
identified previously by mass spectrometry in DNA damage responses.77
ATR is well known for its regulatory role in DDR,
as a DNA damage checkpoint kinase, to signal the presence of DNA damage and to regulate cell cycle checkpoints,57,75,84,85 DNA repair70,86-93 and apoptotic cell death.
ATR suppresses apoptosis through the Chk1 kinase pathway during apoptotic cell death.94 ATR also can localize
to mitochondria via direct interaction with tBid69 and suppress tBid-mediated apoptosis independent of its kinase activity in response to DNA damage by ultraviolet irradiation
and other agents. In addition, ATR promotes nucleotide excision repair (NER) via physical interaction with the repair
protein xeroderma pigmentosum group A (XPA).92 Our
work here indicates that ATR also plays a role in non-DNA
damage stress responses by a novel mechanism. As shown
in Figure 2A, γH2AX and phospho-Chk1-S345, as the important indicators of ATR kinase activity in the DDR, were
not detected in ionomycin-treated cells.
Our results indicate a Ca2+ overload induction of autophosphorylation of ATR on Thr1989, an indicator of kinase-active ATR (Figure 3A). While how Ca2+ overload
activates the ATR-PARP1 anti-necrotic pathway remains to
be determined, our analysis indicates that PARP1 may contain a potential EF hand-like Ca2+ binding motif to which
calcium may bind to activate PARP1. Moreover, our results
reveal that an increase in ATR-PARP1 complex formation
(Figure 6) inhibits PARylation to prevent extension of PAR
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polymers (Figure 5) in response to Ca2+-overload. These
data suggest that ATR may recognize partially PARylated
PARP1. We speculate that the initial auto-PARylation of
PARP1 recruits and then activates ATR to phosphorylate
PARP1, which in turn suppresses further PARP1 activity.
In addition, our results show that ionomycin treatment induced nuclear condensation (Figure 1A) and, interestingly,
this Ca2+-dependent nuclear condensation is PARP1 dependent also (Figure S2C). It has been reported that high calcium levels induce over-condensation of DNA-polycation
complexes in vitro.95-98 Such over-condensation would
induce replication and transcription stresses which might
activate ATR toward PARP1.99,100 However, it is also possible that other unknown Ca2+-dependent proteins or kinases might directly activate the ATR-ATRIP complex via
phosphorylation in a DNA damage-independent manner.
Further investigation into the role of PARP1 PARylation
and the length of the PAR polymers is needed but is out of
scope of the current study.
Interestingly, a PARP1-ATR interaction was reported
previously in cells treated with low doses, but not high
doses, of the DNA damage agent methyl methanesulfonate (MMS). ATR is a substrate for PARylation by PARP1
in this type of DNA damage.72 Inhibition of PARP1 dissociates the ATR-PARP1 complex formed with low dose
of MMS.72 PARP1 also is a sensor of intracellular DNA
damage and replication stress and PARylation is the first
wave of stress signaling for recruiting other DDR factors.101 Clearly, our results indicate that cells respond to
DNA damage and Ca2+ overload by different mechanisms
in terms of the roles of ATR and PARP1. Finally, this report has not specifically addressed how Ca2+ overload activates ATR, but our findings present an interesting insight
deserving of further investigation in the future.
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